Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.54 |
| ▸ | NOS2 | P35228 | 4/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.48 |
| ▸ | GABRE | P78334 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24755263 | 0.83 | NOS2 (0.50) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL555084 | 0.82 | NOS3 (0.54) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL17442658 | 0.80 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL28963852 | 0.80 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL1902299 | 0.80 | NOS3 (0.52) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL10400002 | 0.79 | GABRP (0.46) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL3922995 | 0.78 | NOS3 (0.45) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL25410695 | 0.78 | GABRP (0.55) | NOS3NOS2NOS1GABRPGABRD | |
| SCHEMBL9269242 | 0.77 | CTRC (0.38) | — | |
| SCHEMBL24069972 | 0.77 | NOS3 (0.48) | NOS3NOS2NOS1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-06-04 | — | — | US | disclosed |
| CN-101300236-A | Triazole compounds as lipoxygenase inhibitors | BIOLIPOX AB (SE) | 2008-11-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143440-A1 | Pyrazoles Useful in the Treatment of Inflammation | ALOX15, ALOX12, ALOX15B | NOS3 166/4885NOS2 124/4885NOS1 161/4885 |
| US-20120220561-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | NOS3 319/4885NOS2 535/4885NOS1 437/4885 |
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | NOS3 266/4885NOS2 286/4885NOS1 397/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | NOS3 3501/4885NOS2 2487/4885NOS1 3702/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NOS3 3501/4885NOS2 2487/4885NOS1 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.